SFYB.SG - Synthetic Biologics Inc. Regist

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.268
+0.001 (+0.375%)
At close: 7:15PM CEST
Stock chart is not supported by your current browser
Previous Close0.267
Open0.254
Bid0.000 x 500000
Ask0.000 x 500000
Day's Range0.254 - 0.268
52 Week Range0.224 - 0.875
Volume0
Avg. Volume39
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswirelast month

    Report: Exploring Fundamental Drivers Behind EOG Resources, Alteryx, Synthetic Biologics, Extreme Networks, Knight-Swift Transportation Holdings Inc., and Select Medical — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, March 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
    PR Newswirelast month

    Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

    ROCKVILLE, Md., March 7, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced it has received written communication from NYSE American LLC (the "Exchange"), the Company's current listing exchange, stating that it is not in compliance with certain continued listing standards as set forth in the NYSE American Company Guide. In order to maintain its listing, the Company intends to submit a plan of compliance by April 3, 2018 addressing how it intends to regain compliance with certain Exchange continued listing standards by September 2, 2019. If the plan is accepted, the Company may be able to continue its listing but will be subject to periodic reviews by the Exchange.

  • Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results
    PR Newswire2 months ago

    Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results

    -- Company Provides Update on Late-stage Microbiome-focused Product Candidates -- -- Conference Call Today, February 22, 2018, at 8:30 a.m. (EST) -- ROCKVILLE, Md. , Feb. 22, 2018 /PRNewswire/ --  Synthetic ...

  • ACCESSWIRE2 months ago

    Synthetic Biologics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Synthetic Biologics, Inc. (NYSE: SYN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 8:30 AM Eastern ...

  • Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018
    PR Newswire2 months ago

    Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018

    -- Conference Call Scheduled for Thursday, February 22, 2018 at 8:30 a.m. EST -- ROCKVILLE, Md. , Feb. 15, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference
    PR Newswire4 months ago

    Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference

    ROCKVILLE, Md. , Jan. 2, 2018 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore ...

  • Synthetic Biologics Announces Management Changes
    PR Newswire5 months ago

    Synthetic Biologics Announces Management Changes

    ROCKVILLE, Md., Dec. 5, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steve Shallcross, the Company's Chief Financial Officer, has been named interim CEO to succeed Jeff Riley, who has resigned as an officer and director of the Company, effective immediately, for personal reasons. Jeffrey Kraws, the Company's non-executive Independent Chairman of the Board stated, "The Board is very confident in the ability of Steve Shallcross and Joe Sliman, the Company's Chief Medical Officer, to continue the Company's development activities.

  • CNW Group5 months ago

    ImmunoPrecise Realigns Senior Management

    ImmunoPrecise Realigns Senior Management

  • Associated Press6 months ago

    Synthetic Biologics reports 3Q loss

    The Rockville, Maryland-based company said it had a loss of 14 cents per share. In the final minutes of trading on Wednesday, the company's shares hit 78 cents. A year ago, they were trading at $1.31. ...

  • Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results
    PR Newswire6 months ago

    Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results

    -- Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs -- -- Held Initial Type-B Multidisciplinary Meeting with FDA to Discuss Late-Stage Clinical Advancement for ...

  • Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017
    PR Newswire6 months ago

    Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017

    -- Conference Call Scheduled for Wednesday, November 1, 2017 at 4:30 p.m. EDT -- ROCKVILLE, Md. , Oct. 25, 2017 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • ACCESSWIRE7 months ago

    Today's Research Reports on Stocks to Watch: Synthetic Biologics and Microbot Medical

    NEW YORK, NY / ACCESSWIRE / September 18, 2017 / Shares of both Synthetic Biologics and Microbot Medical soared this past Friday after the companies had exciting news to share with investors. Synthetic ...

  • Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
    PR Newswire7 months ago

    Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing

    ROCKVILLE, Md., Sept. 12, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today the closing of a privately placed stock purchase transaction for the sale of redeemable convertible preferred stock to an affiliate of MSD Partners, L.P. for aggregate gross proceeds of $12 million. Synthetic Biologics intends to use proceeds from the Preferred Stock transaction for general corporate purposes, including the continued advancement of SYN-004 (ribaxamase), the Company's Breakthrough Therapy Designation drug candidate designed to prevent antibiotic-mediated C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR) in the gut microbiome.

  • ACCESSWIRE7 months ago

    Synthetic Biologics, Inc. Provides Company Overview and Update on Clinical Development in New SNNLive Video Interview with StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / September 6, 2017 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Jeff Riley, CEO of Synthetic Biologics, Inc. (NYSE ...

  • Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
    PR Newswire8 months ago

    Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017

    ROCKVILLE, Md., Aug. 29, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. Jeff Riley, President & Chief Executive Officer, will provide an overview of Synthetic Biologics' lead microbiome-focused drug candidates poised for Phase 3 development during a live presentation scheduled for Tuesday, September 12, 2017 at 8:45 a.m. ET and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

  • Associated Press9 months ago

    Synthetic Biologics reports 2Q loss

    The Rockville, Maryland-based company said it had a loss of 3 cents per share. The company's shares closed at 49 cents. A year ago, they were trading at $1.67. _____ This story was generated by Automated ...

  • Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results
    PR Newswire9 months ago

    Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results

    -- SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI -- -- Three Ribaxamase Presentations to be Included at Infectious Disease Week™ (ID Week) 2017 -- -- Conference ...

  • Synthetic Biologics to Report Second Quarter 2017 Operational Highlights and Financial Results on August 3, 2017
    PR Newswire9 months ago

    Synthetic Biologics to Report Second Quarter 2017 Operational Highlights and Financial Results on August 3, 2017

    -- Conference Call Scheduled for Thursday, August 3, 2017 at 8:30 a.m. EDT -- ROCKVILLE, Md. , July 27, 2017 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
    PR Newswire10 months ago

    Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

    ROCKVILLE, Md., June 27, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application which covers the use of the active agent of SYN-010, the Company's proprietary, modified-release formulation of lovastatin lactone, for the treatment of constipation. Upon issuance, this patent will strengthen the intellectual property estate covering the use of SYN-010 for the treatment of IBS-C until at least 2034, affording the Company an extended term for commercialization. U.S. Patent Application No. 14/776,465, which is owned by Cedars-Sinai Medical Center (CSMC) and exclusively licensed to Synthetic Biologics, is based on innovative research led by Mark Pimentel, M.D., FRCP(C), Program Director of CSMC's Medically Associated Science and Technology (MAST) Program and Chairman of Synthetic Biologics' IBS-C Clinical Advisory Board, which correlates methane production in the gut by certain microorganisms (M. smithii) with symptoms commonly associated with IBS-C.

  • Accesswire11 months ago

    Today's Research Reports on Stocks to Watch: Quantum Corporation and Synthetic Biologics

    NEW YORK, NY / ACCESSWIRE / May 24, 2017 / Quantum Corporation saw its shares close up almost 6% yesterday despite no significant press releases. Synthetic Biologics also saw its shares soar and closed ...

  • Accesswire11 months ago

    Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate

    Upcoming AWS Coverage on Corcept Therapeutics Post-Earnings Results LONDON, UK / ACCESSWIRE / May 12, 2017 / Active Wall St. blog coverage looks at the headline from Synthetic Biologics, Inc. (NYSE: SYN ...

  • SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection
    PR Newswire11 months ago

    SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection

    ROCKVILLE, Md., May 11, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for SYN-004 (ribaxamase) for the prevention of Clostridium difficile infection. SYN-004 (ribaxamase) is the Company's first-in-class oral enzyme designed to protect the gut microbiome from disruption caused by certain intravenous (IV) beta-lactam antibiotics.

  • Associated Presslast year

    Synthetic Biologics reports 1Q loss

    On a per-share basis, the Ann Arbor, Michigan-based company said it had a loss of 2 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results
    PR Newswirelast year

    Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results

    ROCKVILLE, Md., May 4, 2017 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health ...